Organization · Venture Capital
VIVES Partners
VIVES Partners is a venture capital fund based in Belgium, initiated by UCLouvain, that invests in early-stage companies with strong academic foundations across Europe. The fund focuses on high-tech sectors including life sciences, AgTech, and engineering.
Overview
What VIVES Partners does
What VIVES Partners is
VIVES Partners is a venture capital fund based in Belgium, initiated by UCLouvain, that invests in early-stage companies with strong academic foundations across Europe. The fund focuses on high-tech sectors including life sciences, AgTech, and engineering.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2004
- Approximate age
- About 22 years
- Structured capabilities
- Funder
- Last reviewed
- March 18, 2026
Official channels
Find VIVES Partners elsewhere
Open the official website or a supported primary organization account.
Capability profile
VIVES Partners as a funder
Investment thesis
VIVES Partners invests in companies that develop disruptive innovations with a positive societal impact, focusing on high-tech sectors.
Focus narrative
VIVES focuses on investing in high-tech companies primarily in three verticals: life sciences, AgTech, and hard engineering. The fund targets early-stage to Series A companies located in Europe, particularly in countries neighboring Belgium. Investments typically range from €100,000 to a maximum of €7 million per line, emphasizing projects with strong intellectual property and significant market potential.
Value beyond capital
VIVES Partners adds value to its portfolio companies by leveraging its expertise in high-tech sectors, providing strategic guidance, and facilitating access to networks that can enhance growth and innovation.
Terms and economics
- Typical check
- $100,000–$7,000,000
Focus and fit
- Stages
- Pre-seed · Seed · Series A · Growth Equity
- Regions
- Europe
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 6
Portfolio context
Notable portfolio companies include: IntoPIX: Specializes in video processing and image compression technologies. ATB Therapeutics: Develops next-generation antibody-drug conjugates for targeted cancer therapies. Nuclidium: Focuses on next-generation radiopharmaceuticals for targeted cancer treatment. Eligo Biosciences: A leader in in vivo gene editing of the microbiome, developing precision medicines. Novadip Biosciences: Works on regenerative medicine, particularly for congenital pseudarthrosis of the tibia. Cissoid: Provides high-temperature semiconductor solutions for power management and conversion.
Common questions
What to know about VIVES Partners
Upseed classifies VIVES Partners under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
March 18, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.